Merck & Co. shares have delivered impressive multi-year returns, climbing over 80% in the past five years. Yet, a deep dive into its valuation metrics suggests the market may still be underestimating the pharmaceutical leader's intrinsic value, presenting a potential opportunity for investors.
Jim Saulnier & Associates reduced its position in the Vanguard 0-3 Month T-Bill ETF by over $5.8 million in Q4, yet short-term Treasuries remain a key liquidity component, accounting for over 5% of its portfolio.
Despite a 6.8% stock decline over six months, lagging the S&P 500, Robinhood's robust user monetization, path to profitability, and strong cash flow present a compelling case for long-term believers.
The third-quarter earnings season for apparel retailers revealed a stark divergence. While some brands like Abercrombie & Fitch soared on strong results, others, including Tilly's and Torrid, faced investor skepticism despite meeting top-line expectations. We analyze the performance, the shifting retail landscape, and what it signals for the sector's future.
While often operating behind the scenes, industrial companies are the engine of the U.S. economy. Bolstered by a favorable interest rate environment, the sector has surged 18.8% in the last six months, significantly outpacing the S&P 500. We analyze two firms with durable competitive edges and one that may be losing momentum.
Bank of Hawaii delivered a robust fourth quarter, but the real story emerged during the analyst Q&A. We examine the critical questions on margins, deposits, and the bank's strategy in a shifting economic landscape.
Crane Company's fourth-quarter earnings outperformed expectations, fueled by robust growth in its Aerospace & Advanced Technologies division. While management celebrated strong execution, analysts on the earnings call zeroed in on the costs and complexities of integrating recent high-profile acquisitions.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
Fresenius SE & Co. KGaA (ETR:FRE) faces a challenging period as its stock declines, with a key profitability metric and a high dividend payout strategy raising questions about its near-term growth prospects.
American Financial Group (AFG) is scheduled to release its fourth-quarter earnings after the market closes on Tuesday, with analysts anticipating flat revenue growth. The report comes as the property & casualty insurance sector faces headwinds from policy uncertainty and market volatility.
Facing an eighth consecutive month of declining deliveries, Li Auto is restructuring its R&D and betting on its upgraded L9 model. Amid a falling share price, analysts debate whether the current valuation presents a buying opportunity or reflects deeper challenges.
The unraveling of the R&R Family of Companies is sending shockwaves through the freight industry, with a new lawsuit from Vantage Carrier alleging over $1.3 million in unpaid invoices. The case adds to a growing pile of legal claims and exposes the precarious financial exposure of carriers and small operators caught in the wake.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
Solid-state battery developer QuantumScape appoints former NVIDIA CFO Geoffrey Ribar to its board, signaling a strategic shift towards manufacturing discipline and capital allocation as it transitions from R&D to pilot production.
Investment firm Needham & Company has reiterated its Buy rating and $21 price target for TeraWulf (WULF), citing the company's strategic shift from Bitcoin mining to high-performance computing and AI infrastructure as a core growth catalyst.
B. Riley analyst Craig Ellis has upgraded Rigetti Computing (NASDAQ: RGTI) from 'Neutral' to 'Buy', maintaining a $35 price target. The upgrade follows the company's announcement of an $8.4 million order to supply a 108-qubit quantum computer to India's premier R&D agency, C-DAC, providing clearer visibility into its 2026 commercial trajectory.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
Kratos Defense & Security Solutions (KTOS) has seen its stock price surge dramatically over the past six months, fueled by strong quarterly performance. However, a closer look at its cash flow, capital efficiency, and valuation suggests investors should proceed with caution. We analyze the risks and highlight a more compelling alternative in the security sector.
The healthcare sector has surged 17.4% in six months, outpacing the S&P 500. While demographic trends fuel long-term growth, regulatory hurdles and valuation concerns demand selective investing. We analyze one company built for decades of returns and two where investors should tread carefully.
The financial services sector, a traditional engine of economic growth, is underperforming the S&P 500 amid economic uncertainty. We examine three specific stocks—Invesco, Enova International, and Sixth Street Specialty Lending—that investors may want to approach with heightened caution.
